APA (7th ed.) Citation

Askarov, V. E., Sultanbaev, A. V., Menshikov, K. V., Chalov, V. S., Sultanbaeva, N. I., & Menshikova, I. A. Combination BRAF/MEK Inhibitor Targeted Therapy and Immunotherapy (atezolizumab + vemurafenib + cobimetinib) for Metastatic Cutaneous Melanoma: Clinical Case. Bashkir State Medical University.

Chicago Style (17th ed.) Citation

Askarov, V. E., A. V. Sultanbaev, K. V. Menshikov, V. S. Chalov, N. I. Sultanbaeva, and I. A. Menshikova. Combination BRAF/MEK Inhibitor Targeted Therapy and Immunotherapy (atezolizumab + Vemurafenib + Cobimetinib) for Metastatic Cutaneous Melanoma: Clinical Case. Bashkir State Medical University.

MLA (9th ed.) Citation

Askarov, V. E., et al. Combination BRAF/MEK Inhibitor Targeted Therapy and Immunotherapy (atezolizumab + Vemurafenib + Cobimetinib) for Metastatic Cutaneous Melanoma: Clinical Case. Bashkir State Medical University.